Research programme: cystic fibrosis transmembrane conductance regulator modulators - Galapagos/AbbVieAlternative Names: Cystic fibrosis therapy research programme - Cystic Fibrosis Foundation/Galapagos; GLPG-2665
Latest Information Update: 19 Oct 2015
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
- Developer AbbVie; Galapagos NV
- Class Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cystic fibrosis